Table 3.

Personalised interventions recommended by the National Institute for Health and Care Excellence (NICE) on the basis of genotype

Technology appraisal numberYear of publicationRelevant genomeTechnologyConditionCategorisationComment
TA3582015GermlineTolvaptanTreating autosomal dominant polycystic kidney diseaseOptimisedOptimised recommendation for tolvaptan as an option for treating autosomal dominant polycystic kidney disease in adults to slow the progression of cyst development and renal insufficiency, only if:

  • they have chronic kidney disease stage 2 or 3 at the start of treatment

  • there is evidence of rapidly progressing disease and the company provides it with the discount agreed in the patient access scheme.

TA3812016GermlineOlaparibTreatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapyOptimisedOptimised recommendation for olaparib as an option for treating adults with relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer who have BRCA1 or BRCA2 mutations and whose disease has responded to platinum-based chemotherapy, only if:

  • they have had three or more courses of platinum- based chemotherapy and

  • the drug cost of olaparib for people who remain on treatment after 15 months will be met by the company.

TA385 (&TA132)2016 (2007)GermlineEzetimibe monotherapyTreating primary heterozygous-familial and non-familial hypercholesterolaemiaRecommendedRecommended in line with marketing authorisation.
TA385 (&TA132)2016 (2007)GermlineEzetimibe co-administered with initial statin therapyTreating primary heterozygous-familial and non-familial hypercholesterolaemiaRecommendedRecommended in line with marketing authorisation.
TA3932016GermlineAlirocumabTreating primary hypercholesterolaemia and mixed dyslipidaemiaOptimisedOptimised recommendation for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:
Low-density lipoprotein concentrations are persistently above the thresholds specified despite maximal tolerated lipid-lowering therapy.
That is, either the maximum dose has been reached or further titration is limited by intolerance (as defined in the NICE guideline for familial hypercholesterolaemia), and the company provides alirocumab with the discount agreed in the patient access scheme.
TA3942016GermlineEvolocumabTreating primary hypercholesterolaemia and mixed dyslipidaemiaOptimisedOptimised recommendation for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:
The dosage is 140 mg every 2 weeks.
Low-density lipoprotein concentrations are persistently above the thresholds specified despite maximal tolerated lipid-lowering therapy. That is, either the maximum dose has been reached, or further titration is limited by intolerance (as defined in the NICE guideline for familial hypercholesterolaemia).
The company provides evolocumab with the discount agreed in the patient access scheme.
TA2512012SomaticNilotinib (first line)Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukemiaRecommendedRecommendation in line with marketing authorisation and following agreement of patient access scheme
TA2512012SomaticStandard-dose imatinib 400 mg per day (first line)Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukemiaRecommendedPartial update of TA70. Recommendation in line with marketing authorisation.
TA2692012SomaticVemurafenibLocally advanced or metastatic BRAF V600 mutation-positive malignant melanomaRecommendedRecommendation in line with marketing authorisation and following agreement of patient access scheme.
TA3212014SomaticDabrafenibUnresectable or metastatic BRAF V600 mutation-positive melanomaRecommendedRecommendation in line with marketing authorisation and following agreement of patient access scheme
TA3222014SomaticLenalidomideMyelodysplastic syndromes associated with an isolated deletion 5q cytogenic abnormalityRecommendedRecommendation in line with marketing authorisation and following agreement of patient access scheme.
TA374 (& TA258)2015 (2012)SomaticErlotinibTreating non-small cell lung cancer that has progressed after chemotherapyOptimisedOptimised recommendation for erlontinib, only if the company provides erlotinib with the discount agreed in the patient access scheme revised in the context of NICE technology appraisal guidance 258. Sections 1.1–1.5 of TA374 summarise guidance for usage.
TA4162016SomaticOsimertinibLocally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancerRecommended (CDF)Recommended in line with clinical practice for use within cancer drugs fund only if the conditions in the managed access agreement for osimertinib are followed.
TA4292017SomaticIbrutinib alonePreviously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutationRecommendedRecommended in line with marketing authorisation and following agreement of a patient access scheme.